CL2020003457A1 - Oligonucleótidos para modular la expresión de tau - Google Patents

Oligonucleótidos para modular la expresión de tau

Info

Publication number
CL2020003457A1
CL2020003457A1 CL2020003457A CL2020003457A CL2020003457A1 CL 2020003457 A1 CL2020003457 A1 CL 2020003457A1 CL 2020003457 A CL2020003457 A CL 2020003457A CL 2020003457 A CL2020003457 A CL 2020003457A CL 2020003457 A1 CL2020003457 A1 CL 2020003457A1
Authority
CL
Chile
Prior art keywords
oligonucleotides
tau
modulate
expression
present
Prior art date
Application number
CL2020003457A
Other languages
English (en)
Inventor
Peter Hagedorn
Richard E Olson
Anja Mølhart Høg
Marianne L Jensen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Priority to CL2021001072A priority Critical patent/CL2021001072A1/es
Priority to CL2021001071A priority patent/CL2021001071A1/es
Publication of CL2020003457A1 publication Critical patent/CL2020003457A1/es
Priority to CL2024003932A priority patent/CL2024003932A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/26—Endoribonucleases producing 5'-phosphomonoesters (3.1.26)
    • C12Y301/26004—Ribonuclease H (3.1.26.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a oligonucleótidos antisentido que pueden modular la expresión de Tau en una célula diana. Los oligonucleótidos se hibridan a mARN de MAPT. La presente invención, además, se refiere a conjugados del oligonucleótido y composiciones farmacéuticas y métodos para el tratamiento de taupatías, enfermedad de Alzheimer, demencia frontotemporal (FTD), FTDP-17, parálisis supranuclear progresiva (PSP), encefalopatía traumática crónica (CTE), degeneración ganglionar corticobasal (CBD), epilepsia, síndrome de Dravet, depresión, trastornos convulsivos y trastornos motores.
CL2020003457A 2018-07-03 2020-12-31 Oligonucleótidos para modular la expresión de tau CL2020003457A1 (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CL2021001072A CL2021001072A1 (es) 2018-07-03 2021-04-26 Oligonucleótidos para modular la expresión de tau (divisional solicitud no. 202003457)
CL2021001071A CL2021001071A1 (es) 2018-07-03 2021-04-26 Oligonucleótidos para modular la expresión de tau (divisional solicitud no. 202003457)
CL2024003932A CL2024003932A1 (es) 2018-07-03 2024-12-18 Oligonucleótido antisentido de 19 a 30 nucleótidos de longitud; conjugado; composición farmacéutica; y su uso.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862693851P 2018-07-03 2018-07-03
US201862726005P 2018-08-31 2018-08-31

Publications (1)

Publication Number Publication Date
CL2020003457A1 true CL2020003457A1 (es) 2021-06-04

Family

ID=67439176

Family Applications (6)

Application Number Title Priority Date Filing Date
CL2020003457A CL2020003457A1 (es) 2018-07-03 2020-12-31 Oligonucleótidos para modular la expresión de tau
CL2021001071A CL2021001071A1 (es) 2018-07-03 2021-04-26 Oligonucleótidos para modular la expresión de tau (divisional solicitud no. 202003457)
CL2021001072A CL2021001072A1 (es) 2018-07-03 2021-04-26 Oligonucleótidos para modular la expresión de tau (divisional solicitud no. 202003457)
CL2024001779A CL2024001779A1 (es) 2018-07-03 2024-06-13 Oligonucleótidos para modular la expresión de tau
CL2024001778A CL2024001778A1 (es) 2018-07-03 2024-06-13 Oligonucleótidos para modular la expresión de tau
CL2024003932A CL2024003932A1 (es) 2018-07-03 2024-12-18 Oligonucleótido antisentido de 19 a 30 nucleótidos de longitud; conjugado; composición farmacéutica; y su uso.

Family Applications After (5)

Application Number Title Priority Date Filing Date
CL2021001071A CL2021001071A1 (es) 2018-07-03 2021-04-26 Oligonucleótidos para modular la expresión de tau (divisional solicitud no. 202003457)
CL2021001072A CL2021001072A1 (es) 2018-07-03 2021-04-26 Oligonucleótidos para modular la expresión de tau (divisional solicitud no. 202003457)
CL2024001779A CL2024001779A1 (es) 2018-07-03 2024-06-13 Oligonucleótidos para modular la expresión de tau
CL2024001778A CL2024001778A1 (es) 2018-07-03 2024-06-13 Oligonucleótidos para modular la expresión de tau
CL2024003932A CL2024003932A1 (es) 2018-07-03 2024-12-18 Oligonucleótido antisentido de 19 a 30 nucleótidos de longitud; conjugado; composición farmacéutica; y su uso.

Country Status (19)

Country Link
US (5) US11279929B2 (es)
EP (1) EP3818159A1 (es)
JP (3) JP7102557B2 (es)
KR (3) KR102723469B1 (es)
CN (2) CN112567033A (es)
AU (2) AU2019297391B2 (es)
BR (1) BR112020026973A2 (es)
CA (2) CA3247235A1 (es)
CL (6) CL2020003457A1 (es)
CR (3) CR20210179A (es)
IL (1) IL279056A (es)
MX (3) MX2020013366A (es)
MY (1) MY206038A (es)
PE (2) PE20210346A1 (es)
PH (1) PH12020552276A1 (es)
RU (1) RU2768285C1 (es)
SG (1) SG11202012759XA (es)
TW (2) TW202519658A (es)
WO (1) WO2020007892A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12163131B2 (en) 2018-07-03 2024-12-10 Hoffmann-La Roche Inc. Oligonucleotides for modulating Tau expression

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2831232A4 (en) 2012-03-30 2015-11-04 Univ Washington METHOD FOR MODULATING TAU EXPRESSION TO REDUCE PROBLEMS AND MODIFY A NEURODEGENERATIVE SYNDROME
CN203618139U (zh) * 2012-08-21 2014-05-28 特电株式会社 流体加热装置
TW202246503A (zh) 2013-07-19 2022-12-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
WO2019157531A1 (en) 2018-02-12 2019-08-15 Ionis Pharmaceuticals, Inc. Modified compounds and uses thereof
JP2023515862A (ja) * 2020-03-01 2023-04-14 ウェイブ ライフ サイエンシズ リミテッド オリゴヌクレオチド組成物及びその方法
AU2021246024A1 (en) * 2020-03-30 2022-10-27 Alnylam Pharmaceuticals, Inc. Microtubule associated protein Tau (MAPT) iRNA agent compositions and methods of use thereof
TW202310854A (zh) * 2021-07-23 2023-03-16 美商百健Ｍａ公司 用於減少ｔａｕ表現之方法
US20250283084A1 (en) * 2024-03-08 2025-09-11 Eli Lilly And Company Mapt antisense oligonucleotide

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
DE69233046T2 (de) 1991-10-24 2004-03-04 Isis Pharmaceuticals, Inc., Carlsfeld Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
JP4236812B2 (ja) 1997-09-12 2009-03-11 エクシコン エ／エス オリゴヌクレオチド類似体
ES2234563T5 (es) 1999-02-12 2018-01-17 Daiichi Sankyo Company, Limited Nuevos análogos de nucleósidos y oligonucleótidos
US7053207B2 (en) 1999-05-04 2006-05-30 Exiqon A/S L-ribo-LNA analogues
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
WO2003022987A2 (en) 2001-07-26 2003-03-20 Eos Biotechnology, Inc. Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
AU2003295600A1 (en) 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
WO2004046160A2 (en) 2002-11-18 2004-06-03 Santaris Pharma A/S Amino-lna, thio-lna and alpha-l-oxy-ln
US7250289B2 (en) * 2002-11-20 2007-07-31 Affymetrix, Inc. Methods of genetic analysis of mouse
US20060257851A1 (en) 2002-11-26 2006-11-16 Itzhak Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
EP2270162B1 (en) 2003-06-12 2018-10-03 Alnylam Pharmaceuticals Inc. Conserved hbv and hcv sequences useful for gene silencing
US20050244851A1 (en) 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
US7374927B2 (en) 2004-05-03 2008-05-20 Affymetrix, Inc. Methods of analysis of degraded nucleic acid samples
WO2005116204A1 (ja) 2004-05-11 2005-12-08 Rnai Co., Ltd. Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法
US20070154896A1 (en) 2005-02-11 2007-07-05 International Business Machines Corporation System and method for identification of MicroRNA target sites and corresponding targeting MicroRNA sequences
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
WO2007090071A2 (en) 2006-01-27 2007-08-09 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
AU2007225238A1 (en) 2006-03-10 2007-09-20 Wyeth Microarray for monitoring gene expression in multiple strains of Streptococcus pneumoniae
JP2009536222A (ja) 2006-05-05 2009-10-08 アイシス ファーマシューティカルズ， インコーポレーテッド Ｐｃｓｋ９の発現を調節するための化合物および方法
AU2007249349B2 (en) 2006-05-11 2012-03-08 Isis Pharmaceuticals, Inc. 5'-Modified bicyclic nucleic acid analogs
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
ES2526295T5 (es) * 2006-10-18 2021-05-04 Ionis Pharmaceuticals Inc Compuestos antisentido
DK2149605T3 (da) 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
CA2688321A1 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
DK2173760T4 (en) 2007-06-08 2016-02-08 Isis Pharmaceuticals Inc Carbocyclic bicyclic nukleinsyreanaloge
AU2008272918B2 (en) 2007-07-05 2012-09-13 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
WO2009067647A1 (en) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs
WO2009090182A1 (en) 2008-01-14 2009-07-23 Santaris Pharma A/S C4'-substituted - dna nucleotide gapmer oligonucleotides
US9290534B2 (en) 2008-04-04 2016-03-22 Ionis Pharmaceuticals, Inc. Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside
WO2010006111A2 (en) 2008-07-10 2010-01-14 Merck & Co., Inc. Methods of using compositions comprising mir-192 and/or mir-215 for the treatment of cancer
DK2356129T3 (da) 2008-09-24 2013-05-13 Isis Pharmaceuticals Inc Substituerede alpha-L-bicykliske nukleosider
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
KR101728655B1 (ko) 2008-12-18 2017-04-19 다이서나 파마수이티컬, 인크. 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
US9012421B2 (en) 2009-08-06 2015-04-21 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
EP2580228B1 (en) 2010-06-08 2016-03-23 Ionis Pharmaceuticals, Inc. Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
US9029341B2 (en) 2010-08-17 2015-05-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
KR101865433B1 (ko) 2010-10-22 2018-07-13 큐알엔에이, 인크. 알파-l 이두로니다아제 (idua)에 대한 자연 안티센스 전사체의 저해에 의한 idua 관련된 질환의 치료
LT3124610T (lt) 2010-10-28 2019-08-12 Benitec Biopharma Limited Hbv gydymas
EP2673361B1 (en) 2011-02-08 2016-04-13 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
RU2013150331A (ru) 2011-04-20 2015-05-27 Рош Гликарт Аг СПОСОБ И УСТРОЙСТВА ДЛЯ рН-ЗАВИСИМОГО ПРОХОЖДЕНИЯ ГЕМАТОЭНЦЕФАЛИЧЕСКОГО БАРЬЕРА
RS61447B1 (sr) 2011-04-21 2021-03-31 Glaxo Group Ltd Modulacija ekspresije virusa hepatitisa b (hbv)
EA024762B9 (ru) 2011-06-30 2017-04-28 Эрроухэд Рисерч Корпорейшн Композиции и способы ингибирования экспрессии генов вируса гепатита в
US10202599B2 (en) 2011-08-11 2019-02-12 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
EP2753631A1 (en) 2011-09-07 2014-07-16 Marina Biotech, Inc. Synthesis and uses of nucleic acid compounds with conformationally restricted monomers
ME03008B (me) * 2011-09-19 2018-10-20 Axon Neuroscience Se Terapija na osnovu proteina i dijagnoza patologije u којој posreduje tau u alcнajмerovoj bolesti
EP2831232A4 (en) 2012-03-30 2015-11-04 Univ Washington METHOD FOR MODULATING TAU EXPRESSION TO REDUCE PROBLEMS AND MODIFY A NEURODEGENERATIVE SYNDROME
EP2850092B1 (en) 2012-04-09 2017-03-01 Ionis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
WO2013159109A1 (en) 2012-04-20 2013-10-24 Isis Pharmaceuticals, Inc. Modulation of hepatitis b virus (hbv) expression
WO2013166264A2 (en) 2012-05-02 2013-11-07 University Of Georgia Research Foundation, Inc. Methods for altering virus replication
BR112014028645A2 (pt) * 2012-05-16 2017-06-27 Rana Therapeutics Inc composições e métodos para modulação da expressão de apoa1 e abca1.
KR102213609B1 (ko) 2012-07-13 2021-02-08 웨이브 라이프 사이언시스 리미티드 키랄 제어
CA2882966A1 (en) 2012-08-31 2014-03-06 Aptamir Therapeutics, Inc. Mirna modulators of chronic visceral inflammation
CN104837996A (zh) 2012-11-15 2015-08-12 罗氏创新中心哥本哈根有限公司 抗apob反义缀合物化合物
CN105264091B (zh) 2013-03-14 2020-02-28 Ionis制药公司 用于调节tau表达的组合物和方法
DK2992098T3 (da) 2013-05-01 2019-06-17 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression
HUE048738T2 (hu) 2013-06-27 2020-08-28 Roche Innovation Ct Copenhagen As Antiszensz oligomerek és konjugátumok, amelyek a PCK9-t célozzák meg
CA2917229A1 (en) 2013-07-02 2015-01-08 Isis Pharmaceuticals, Inc. Modulators of growth hormone receptor
TW202246503A (zh) 2013-07-19 2022-12-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
CN105980615A (zh) 2013-08-28 2016-09-28 卡里斯生命科学瑞士控股有限公司 寡核苷酸探针及其用途
EA201691261A1 (ru) 2014-01-30 2016-11-30 Ф. Хоффманн-Ля Рош Аг Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
CA2935426C (en) 2014-01-30 2023-07-25 F. Hoffmann-La Roche Ag Polyoligomer compound with biocleavable conjugates for reducing or inhibiting expression of a nucleic acid target
KR20160148715A (ko) 2014-05-13 2016-12-26 에프. 호프만-라 로슈 아게 B형 간염 바이러스 감염의 치료 또는 예방을 위한 신규한 다이하이드로퀴놀리진온
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
WO2016019063A1 (en) * 2014-07-29 2016-02-04 Isis Pharmaceuticals, Inc. Compositions and methods for modulating tau expression
CN106795200B (zh) 2014-10-10 2020-06-19 豪夫迈·罗氏有限公司 Galnac亚磷酰胺、其核酸缀合物及其用途
WO2016079183A1 (en) 2014-11-19 2016-05-26 Roche Innovation Center Copenhagen A/S Lna chiral phosphorothioates
US11077132B2 (en) 2015-02-04 2021-08-03 F. Hoffmann-La Roche Ag Tau antisense oligomers and uses thereof
WO2016127002A1 (en) 2015-02-04 2016-08-11 Bristol-Myers Squibb Company Lna oligonucleotides with alternating flanks
HK1244281B (zh) 2015-02-11 2020-02-07 F. Hoffmann-La Roche Ag 治疗和预防乙型肝炎病毒感染的2-氧代-6，7-二氢苯并[a]喹嗪-3-甲酸衍生物
US10513701B2 (en) 2015-03-25 2019-12-24 Università Degli Studi Di Trento RNA interference mediated therapy for neurodegenerative diseases
WO2016177655A1 (en) 2015-05-04 2016-11-10 F. Hoffmann-La Roche Ag Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections
EP3322661B1 (en) 2015-07-13 2022-03-02 Otis Elevator Company Deterrent device inhibition key
CA2996722A1 (en) 2015-07-17 2017-01-26 Arcturus Therapeutics, Inc. Compositions and agents against hepatitis b virus and uses thereof
AU2016306275A1 (en) 2015-08-07 2018-02-08 Arrowhead Pharmaceuticals, Inc. RNAi therapy for Hepatitis B virus infection
WO2017066712A2 (en) 2015-10-16 2017-04-20 The Children's Medical Center Corporation Modulators of telomere disease
JP7036723B2 (ja) * 2015-12-14 2022-03-15 コールド スプリング ハーバー ラボラトリー 眼疾患の処置のための組成物および方法
PH12018501207B1 (en) 2015-12-21 2024-02-23 Novartis Ag Compositions and methods for decreasing tau expression
WO2017178656A1 (en) 2016-04-14 2017-10-19 Roche Innovation Center Copenhagen A/S TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE
EP4219767A1 (en) 2016-06-17 2023-08-02 F. Hoffmann-La Roche AG Papd5 and papd7 inhibitors for treating a hepatitis b infection
HUE065170T2 (hu) * 2016-09-29 2024-05-28 Biogen Ma Inc Vegyületek és módszerek a TAU expresszió csökkentésére
WO2018059718A1 (en) 2016-09-30 2018-04-05 Rijk Zwaan Zaadteelt En Zaadhandel B.V. Peronospora resistance in spinacia oleracea
CN111511914B (zh) 2017-10-16 2023-11-17 豪夫迈·罗氏有限公司 减少PAPD5和PAPD7 mRNA的核酸分子用于治疗乙型肝炎感染
IL276043B2 (en) 2018-01-29 2024-06-01 Hoffmann La Roche Process for the preparation of galnac oligonucleotide conjugates
PE20210346A1 (es) 2018-07-03 2021-02-25 Hoffmann La Roche Oligonucleotidos para modular la expresion de tau

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12163131B2 (en) 2018-07-03 2024-12-10 Hoffmann-La Roche Inc. Oligonucleotides for modulating Tau expression

Also Published As

Publication number Publication date
CN112567033A (zh) 2021-03-26
US20250051777A1 (en) 2025-02-13
PE20220013A1 (es) 2022-01-11
AU2023202255A1 (en) 2023-05-11
CL2024001779A1 (es) 2024-10-25
KR102723469B1 (ko) 2024-10-31
PH12020552276A1 (en) 2021-07-12
JP2022141739A (ja) 2022-09-29
KR20210028235A (ko) 2021-03-11
WO2020007892A1 (en) 2020-01-09
EP3818159A1 (en) 2021-05-12
TW202020151A (zh) 2020-06-01
SG11202012759XA (en) 2021-01-28
KR102585973B1 (ko) 2023-10-10
CR20210058A (es) 2021-03-22
US20240026360A1 (en) 2024-01-25
KR20240157136A (ko) 2024-10-31
AU2023202255B2 (en) 2025-07-10
US11279929B2 (en) 2022-03-22
MX2025000063A (es) 2025-02-10
CR20210179A (es) 2022-05-23
US12163131B2 (en) 2024-12-10
TWI862501B (zh) 2024-11-21
MY206038A (en) 2024-11-26
US20210123054A1 (en) 2021-04-29
NZ770352A (en) 2024-07-05
CR20210178A (es) 2021-05-11
MX2020013366A (es) 2021-03-09
AU2019297391A1 (en) 2020-12-24
CL2024003932A1 (es) 2025-04-21
CA3103054C (en) 2026-02-17
CN120137967A (zh) 2025-06-13
CA3247235A1 (en) 2025-11-29
JP7604423B2 (ja) 2024-12-23
JP2025029212A (ja) 2025-03-05
US20220177884A1 (en) 2022-06-09
AU2019297391B2 (en) 2023-01-12
IL279056A (en) 2021-01-31
CL2021001071A1 (es) 2021-10-15
MX2025000060A (es) 2025-02-10
JP2021529525A (ja) 2021-11-04
PE20210346A1 (es) 2021-02-25
JP7102557B2 (ja) 2022-07-19
KR20230143199A (ko) 2023-10-11
RU2768285C1 (ru) 2022-03-23
CL2024001778A1 (es) 2024-09-27
US11753640B2 (en) 2023-09-12
CA3103054A1 (en) 2020-01-09
US20200010831A1 (en) 2020-01-09
TW202519658A (zh) 2025-05-16
BR112020026973A2 (pt) 2021-04-06
CL2021001072A1 (es) 2021-10-15

Similar Documents

Publication Publication Date Title
CL2020003457A1 (es) Oligonucleótidos para modular la expresión de tau
CL2009000860A1 (es) Compuestos derivados de 4-fenil-4-metil-5,6-dihidro-4h-1,3-tiazina-2-amina; composiciones farmaceuticas que los contienen; y uso de los compuestos en la preparacion de medicamentos inhibidores de bace, utiles para el tratamiento de trastornos mediados por esta enzima, tal como la enfermedad de alzheimer.
ECSP099061A (es) Moduladores de benzofuro- y benzotienopirimidina
CL2008002744A1 (es) Compuestos derivados de 1,3-disustituidos-4-fenil-1h-piridin-2-ona, moduladores alostericos del receptor glutamatérgico mglur2; composición farmacéutica y uso de los compuestos en el tratamiento de afecciones neurológicas y siquiatricas mediadas por mglur2.
CR20110103A (es) Heteroarilos sustituidos
BR112023020781A2 (pt) Moduladores de cbl-b e usos dos mesmos
NI200900159A (es) Moduladores de 2-aminopirimidina del receptor de histamina h4.
PH12016501791B1 (en) Muscarinic receptor agonists
MX385975B (es) Moduladores alostéricos positivos del receptor de acetilcolina muscarínico m1.
PA8808201A1 (es) Moduladores imidazolo-,oxazolo-, y tiazolopirimidina del trpvi
BR112015022156A2 (pt) composições e métodos para modular a expressão de tau
CL2017003124A1 (es) Moduladores alostéricos positivos del receptor de m2 muscarínico
NI201000214A (es) Moduladores de diamino-piridina, pirimidina, y piridazina del receptor de la histamina h4.
NI201000168A (es) Aminas de tiazolopiridina-2-iloxi-fenil y tiazolopirazina-2-iloxi-fenil como moduladores del leucotrieno a4 hidrolasa.
CL2015002434A1 (es) Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina.
CL2012001031A1 (es) Compuestos derivados de 2-oxo-1-pirrolidinil-imidazotiadiazol; composición farmacéutica que los comprende; útiles para el tratamiento de la epilepsia, transtornos neurológicos, entre otros.
UY32641A (es) Compuestos con dos porciones heteroarilo bicíclicas fusionadas como moduladores de la hidrolasa de leucotrieno a4
CL2020002038A1 (es) Oligonucleótidos para modular la expresión de tmem106b.
AR109750A1 (es) Compuestos y métodos para reducir la expresión de tau
CL2016000677A1 (es) Compuestos derivados de etinilo, moduladores alostericos positivos del receptor mglur4; composicion farmaceutica que los comprende; y su uso en enfermedades del snc, cancer y diabetes tipo 2.
AR116104A1 (es) Oligonucleótidos para modular la expresión de tau
BR112017019154A2 (pt) uso de frações isoladas de goma mástica para o tratamento de neuropatia óptica
CL2022002713A1 (es) Oligonucleótidos para modular la expresión de tau (divisional solicitud no. 202003457)
CU20180044A7 (es) Derivados novedosos de diamino piridina
BR112017014229A2 (pt) conjugado, composição, e, método para tratamento de um distúrbio.